(10)    Grant Income

In September 2024, the Company received its second award (the “2024 Award”) from the National Cancer Institute of the National Institutes of Health (the “NIH”). The 2024 Award is a two-year, Direct to Phase II, SBIR Award to support IND-enabling and clinical trial activities in the Company’s clinical trial with its lead candidate, TTX-MC138. The total 2024 Award is for $1,999,972 of which $1,011,207 applies to the first year and $988,765 applies to the second year. Income under the grant is recognized as work under the grant is completed. The Company recognized grant income of $21,316 and $153,685 for the three months ended June 30, 2026 and 2025, respectively, and $161,151 and $501,529, respectively, for the six months ended June 30, 2026 and 2025. The Company recorded grant income receivable of $0 and $952,460 at June 30, 2026, and December 31, 2025, respectively. The Company had deferred grant income of $63,947 and $0 at June 30, 2026, and December 31, 2025, respectively.